Wu Bocheng, Chang Heng Jui, Singh Prashant, Hostetler Alexander, Xiang Yichen, Guo Shenghao, Wang Fiona Yihan, Zhong Julia J, Leifer Becky S, Schiavoni Richard P, Jiang Nan, Choudhary Amit, Westcott Peter M K, Koehler Angela N
Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge MA 02139.
Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02142.
bioRxiv. 2025 Jun 18:2025.03.03.641115. doi: 10.1101/2025.03.03.641115.
The TOX protein (thymocyte selection-associated high mobility group box) is a critical transcription factor implicated in both T acute lymphoblastic leukemia (T-ALL) and CD8 T cell exhaustion. Gene perturbation studies suggest that inhibiting TOX may have therapeutic implications for both leukemia and T cell exhaustion. However, due to its complex molecular mechanisms and intrinsically disordered structure, TOX has not been effectively targeted by small molecules to date. In this study, we used small molecule microarray (SMM) screening and biochemical assays to identify a series of TOX protein-protein interaction (PPI) inhibitors. We identified as a TOX protein binder and potent TOX PPI inhibitor. In T-ALL, revealed selective cytotoxicity and proteosome-dependent TOX degradation. In CD8 T cells, potently reversed T cell exhaustion by decreasing surface inhibitory receptors, increasing expression of effector cytokines, and enhancing cancer cell killing activity. We also demonstrate the utility of to probe potential epigenetic regulatory mechanisms of TOX via KAT7 acetylation in T cells.
TOX蛋白(胸腺细胞选择相关高迁移率族框蛋白)是一种关键的转录因子,与T急性淋巴细胞白血病(T-ALL)和CD8 T细胞耗竭均有关联。基因扰动研究表明,抑制TOX可能对白血病和T细胞耗竭都具有治疗意义。然而,由于其复杂的分子机制和内在无序的结构,迄今为止TOX尚未被小分子有效靶向。在本研究中,我们使用小分子微阵列(SMM)筛选和生化分析来鉴定一系列TOX蛋白-蛋白相互作用(PPI)抑制剂。我们鉴定出一种TOX蛋白结合剂和强效的TOX PPI抑制剂。在T-ALL中,该抑制剂显示出选择性细胞毒性和蛋白酶体依赖性的TOX降解。在CD8 T细胞中,该抑制剂通过减少表面抑制性受体、增加效应细胞因子的表达以及增强癌细胞杀伤活性,有力地逆转了T细胞耗竭。我们还证明了该抑制剂可用于通过T细胞中KAT7乙酰化来探究TOX潜在的表观遗传调控机制。